Belimumab in systemic lupus erythematosus: a profile of its use

摘要: Belimumab (Benlysta®), a human immunoglobulin (Ig) G1λ monoclonal antibody targeting B lymphocyte stimulator, is effective as an add-on to standard therapy in patients with active, autoantibody-positive systemic lupus erythematosus (SLE). was first approved 2011 intravenous (IV) treatment for adults SLE. Since then, subcutaneous formulation of belimumab has been and, most recently, IV children aged ≥ 5 years. In SLE, improves overall disease activity and flare rates. appears have steroid-sparing effect control maintained over long-term use. The clinical benefits SLE are consistent those adults. generally well tolerated both children.